RT Journal Article
SR Electronic
T1 The effect of climate change on Yellow Fever disease burden in Africa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.25.20026369
DO 10.1101/2020.02.25.20026369
A1 Katy Gaythorpe
A1 Arran Hamlet
A1 Laurence Cibrelus
A1 Tini Garske
A1 Neil Ferguson
YR 2020
UL http://medrxiv.org/content/early/2020/02/25/2020.02.25.20026369.abstract
AB Yellow Fever (YF) is an arbovirus capable of causing haemorrhagic fever which is endemic in tropical regions of Africa and South America. In recent years, it has resurged – leading to large outbreaks and expanding its endemic zone, the causes of which are unknown. In Africa, the disease is currently considered endemic in 34 countries where it is estimated to cause 78,000 deaths a year. As the mosquito vectors of YF sensitive to environmental conditions, climate change may have substantial effects on the transmission of YF. Here we present the first analysis of the potential impact of climate change on YF transmission and disease burden. We extend an existing model of YF transmission in Africa to account for rainfall and a temperature suitability index. From this, we project transmission intensity across the African endemic region in the context of four climate change scenarios (representative concentration pathways (RCPs) 2.6, 4.5, 6.0 and 8.5). We use these transmission projections to assess the change from current to future disease burden in 2050 and 2070 for each emission scenario. We find that disease burden changes heterogeneously with temperature and rainfall across the region. In RCP 2.6, we find a 93.0% [95% CI 92.7, 93.2%] chance that deaths will increase in 2050. We find that the annual expected number of deaths may increase by between 10.8% [95% CrI -2.4, 37.9%] for RCP 2.6 and 24.9% [95% CrI -2.2, 88.3%] for RCP 8.5 in 2050, with the most notable changes occurring in East and Central Africa. Changes in temperature and rainfall will affect the transmission dynamics of YF. Such a change in epidemiology will complicate future control efforts. As such, we may need to consider the effect of changing climactic variables on future intervention strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementBill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) Valid : Katy A. M. Gaythorpe, Tini Garske OPP1117543 Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) Valid : Katy A. M. Gaythorpe, Tini Garske OPP1157270 Medical Research Council (MRC) Valid : Katy A. M. Gaythorpe, Arran Hamlet, Tini Garske, Neil M Ferguson MR/R015600/1 This work was carried out as part of the Vaccine Impact Modelling Consortium (www.vaccineimpact.org), but the views expressed are those of the authors and not necessarily those of the Consortium or its funders. The funders were given the opportunity to review this paper prior to publication, but the final decision on the content of the publication was taken by the authors. We acknowledge joint Centre funding from the UK Medical Research Council and Department for International Development. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData Availability: Public repository data: Vaccination coverage: coverage is available to download from the PoLiCi shiny app : https://shiny.dide.imperial.ac.uk/polici/. Serology surveys: There are seven published surveys used, available at DOI:10.1016/0147-9571(90)90521-T, DOI:10.1093/trstmh/tru086, DOI: 10.1186/s12889-018-5726-9, DOI: 10.4269/ajtmh.2006.74.1078, PMID: 3501739, PMID: 4004378, PMID: 3731366 Demographic data: Population level data was obtained from UN WPP https://population.un.org/wpp/, this was disaggregated using Landscan 2014 data https://landscan.ornl.gov/landscan-data-availability. Environmental data: This was obtained from LP DAAC: https://lpdaac.usgs.gov/ and worldclim http://www.worldclim.org/ Yellow fever outbreaks: These were compiled from the WHO weekly epidemiologic record and disease outbreak news https://www.who.int/wer/en/ and https://www.who.int/csr/don/en/. Data elsewhere: The data from the WHO YF surveillance database and from recent serological surveys from WHO member states in Africa underlying the results presented in the study are available from World Health Organization (contact: William Perea, pereaw{at}who.int or Laurence Cibrelus, cibrelusl{at}who.int or Jennifer Horton, jhorton{at}who.int).